title: [Treatment strategies in ovarian cancer].
abstract: Surgery is the cornerstone of the treatment The goal of the surgery is an optimal (no residual tumor) resection on the tumor. The combination of carboplatin and paclitaxel has been the standard chemotherapy in first line setting. The treatment of the recurrent disease depends of the disease free interval. The patients that relapse over 6 months after the the previous treatment are treated with platinum based chemotherapy. For the patients who relapse within 6 months, non-platinum agents are selected. Bevacizumab has improved the efficacy of the cytotoxic chemotherapy in first line as well as in the second line treatment. The challenge in the future is a tailored treatment according to the biomolecular characteristics of the tumor.
authors.affiliation: OYS:n naistentautien klinikka.
authors.forename: Ulla
authors.initials: U
authors.lastname: Puistola
authors.forename: Arto
authors.initials: A
authors.lastname: Leminen
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000068258:Bevacizumab; D016190:Carboplatin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000628:therapy; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000601:surgery*; D017239:Paclitaxel / Q000627:therapeutic use
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068258:Bevacizumab; D016190:Carboplatin; D017239:Paclitaxel